Biolidics shares sink 22% after calling off US sales of Covid-19 test kits
Add BT as a preferred sourceSingapore
BIOLIDICS shares sank 22 per cent on Monday after the Catalist-listed firm announced on Sunday that it had mutually agreed with Aytu BioScience to terminate a distribution agreement for its Covid-19 antibody test kits in the US, amid increased competition for such kits.
Shares of Biolidics, which ended Friday at 41 Singapore cents, plunged to 29.5 cents as at 8.58am on Monday. The stock recovered to 35 cents as at 9.26am, before closing at 32 cents, down nine cents.
TRENDING NOW
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Koh Brothers Eco Engineering faces up to S$57.6 million in potential liabilities from legal disputes
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
DayOne secures S$530 million green loan from DBS, OCBC and UOB for Singapore data centre
